BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gemtuzumab Ozogamicin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gemtuzumab Ozogamicin\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03737955-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT03737955)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Dise
 ase in Patients With Acute Myeloid Leukemia\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ge
 mtuzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03737955
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558124-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Gemtuzumab Ozogamicin: Phase 1 readout est. (NCT05558124)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 1\, Acute Myeloid Leukemia.\nStud
 y: CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AM
 L\nEstimated primary completion: April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05558124
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04385290-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Gemtuzumab Ozogamicin: Phase 1/2 readout est. (NCT04385290)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 1/2\, Acute Myeloid Leukemia.\nSt
 udy: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line St
 andard Therapy for Acute Myeloid Leukemia (MOSAIC)\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 emtuzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04385290
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04050280-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT04050280)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: CLAG-GO for Patients With Persistent\, Relapsed or Refractory AML\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04050280
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917911-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271125
DTEND;VALUE=DATE:20271126
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT06917911)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usu
 al Treatment Regimen (Cytarabine and Daunorubicin\, "7+3") for Core Bindin
 g Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATC
 H Treatment Trial)\nEstimated primary completion: 25 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06917911
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01409161-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT01409161)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in
  Treating Patients With Previously Untreated Acute Promyelocytic Leukemia\
 nEstimated primary completion: 18 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT01409161
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03589729-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT03589729)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of C
 hemotherapy in Participants With Blood Cancers\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gemtuzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03589729
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05199051-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT05199051)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination 
 in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML\nEsti
 mated primary completion: 10 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05199051
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00801489-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281011
DTEND;VALUE=DATE:20281012
SUMMARY:Gemtuzumab Ozogamicin: Phase 2 readout est. (NCT00801489)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 2\, Acute Myeloid Leukemia.\nStud
 y: Fludarabine Phosphate\, Cytarabine\, Filgrastim-sndz\, Gemtuzumab Ozoga
 micin\, and Idarubicin Hydrochloride in Treating Patients With Newly Diagn
 osed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome\nEstimat
 ed primary completion: 11 October 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT00801489
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448013-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gemtuzumab Ozogamicin: Phase 1 readout est. (NCT06448013)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 1\, Acute Myeloid Leukemia.\nStud
 y: A Phase I Study Investigating the Combination of the Menin Inhibitor Zi
 ftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute M
 yeloid Leukemia\nEstimated primary completion: 31 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06448013
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05662904-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Gemtuzumab Ozogamicin: Phase 1 readout est. (NCT05662904)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 1\, Acute Myeloid Leukemia.\nStud
 y: Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD3
 3-directed Immunotherapy in Patients with AML\nEstimated primary completio
 n: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gemt
 uzumab-ozogamicin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05662904
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or
  Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 M
 utations\nEstimated primary completion: 30 June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04293562
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02724163-2842@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Gemtuzumab Ozogamicin: Phase 3 readout est. (NCT02724163)
DESCRIPTION:Gemtuzumab Ozogamicin\, phase 3\, Acute Myeloid Leukemia.\nStud
 y: International Randomised Phase III Clinical Trial in Children With Acut
 e Myeloid Leukaemia\nEstimated primary completion: December 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02724163
URL:https://assetmemo.bio/drug/gemtuzumab-ozogamicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
